Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

ABSTRACT:

Purpose of review

The autologous antigen-presenting cell immunotherapy, sipuleucel-T, was the first and remains the only US Food and Drug Administration-approved immunotherapy for prostate cancer. In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials.

Recent findings

Multiple studies are now testing sipuleucel-T in different disease settings and/or in combination with conventional and novel hormonal therapies. In addition, a poxviral-based vaccine has shown promise in early-phase clinical studies and has now entered phase 3 testing in men with metastatic prostate cancer. Next, a DNA vaccine has been evaluated in men with biochemically recurrent prostate cancer and has shown earl

SUBMITTER: Antonarakis ES 

PROVIDER: S-EPMC3444804 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature